New York City DEA Diversion Investigation Lawyer
The Drug Enforcement Administration’s diversion control program operates quietly and methodically, targeting licensed medical professionals, pharmacists, distributors, and others who handle controlled substances lawfully. When the DEA opens a diversion investigation, it rarely announces itself with a knock at the door. Subpoenas arrive at pharmacies. Prescription drug monitoring data gets pulled. Undercover agents present as patients. By the time a target realizes an investigation is underway, federal agents may have been building their case for months. If you are under scrutiny from the DEA’s Diversion Control Division, working with a New York City DEA diversion investigation lawyer before charges are filed can mean the difference between a licensing matter and a federal indictment.
Diversion cases are not conventional drug prosecutions. They sit at the intersection of federal criminal law, administrative regulatory enforcement, and professional licensing. A physician, nurse practitioner, or pharmacy owner accused of diverting controlled substances faces potential DEA registration revocation, loss of state licensure, civil money penalties, and federal criminal prosecution under the Controlled Substances Act, often simultaneously. Each of those tracks moves on its own timeline, with its own evidentiary standards and procedural rules. Defending one without regard for the others is a strategic mistake that can compound the damage.
New York presents a particularly intense enforcement environment. The DEA’s New York Division oversees one of the busiest pharmaceutical markets in the country. Federal prosecutors in both the Southern District of New York and the Eastern District of New York have made diversion a priority, particularly in the wake of ongoing scrutiny over opioid prescribing. State regulators at the New York State Department of Health and the Office of Professional Medical Conduct move in parallel with federal investigators. Getting ahead of all of this requires someone who understands how federal investigations develop and where intervention points actually exist.
How DEA Diversion Investigations Unfold in New York
DEA diversion investigations do not begin randomly. They are triggered by data. The DEA’s Automation of Reports and Consolidated Orders System, combined with New York’s Prescription Monitoring Program Registry, flags prescribers and dispensers whose controlled substance activity falls outside statistical norms. A physician writing high volumes of Schedule II opioids, a pharmacy dispensing patterns that diverge sharply from regional averages, or a distributor whose order quantities spike without explanation, these anomalies generate reports that land on a diversion investigator’s desk.
From there, the investigation builds in layers. Investigators conduct administrative inspections of DEA registrants without advance notice or a warrant. They issue administrative subpoenas for prescription records, financial records, and patient files. They interview former employees, patients, and business partners. In more serious cases, they coordinate with the U.S. Attorney’s Office and use grand jury subpoenas, wiretaps, and undercover operations. This layered approach means that by the time a federal criminal attorney enters the picture, the government has often already developed substantial evidence.
Early retention of a New York DEA diversion attorney changes that dynamic. Counsel can monitor subpoena compliance to prevent inadvertent waiver of rights, engage with DEA investigators to shape the narrative at an early stage, identify procedural defects in the government’s approach, and assess whether cooperation or aggressive contestation best serves the client’s specific situation. At the Law Offices of Jason Goldman, pre-arrest investigation work is a defined practice area, not an afterthought.
What This Practice Covers: DEA Diversion Defense in New York
- Unlawful Prescribing Allegations: Federal law requires that controlled substance prescriptions be issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice. DEA diversion cases frequently allege that a physician or advanced practice provider failed to meet this standard, often targeting pain management specialists, psychiatrists, and urgent care physicians operating in high-volume New York practices.
- Pharmacy Diversion and Dispensing Violations: Pharmacies that fill prescriptions without adequate verification, dispense quantities inconsistent with patient need, or maintain inadequate recordkeeping face DEA administrative action and potential federal charges. New York pharmacies in high-density urban markets are disproportionately subject to DEA audits.
- DEA Registration Revocation Proceedings: An order to show cause initiating revocation of a DEA registration is a separate administrative action that can proceed independently of any criminal case. Defending a registration before a DEA Administrative Law Judge requires different expertise than criminal defense, and losing registration can end a medical career regardless of any criminal outcome.
- Distributor and Manufacturer Diversion: Wholesale distributors and pharmaceutical manufacturers are required to maintain effective controls against diversion and to report suspicious orders. Allegations that a distributor failed these obligations have resulted in some of the largest enforcement actions in federal regulatory history, and smaller New York-based distributors face the same legal framework.
- Healthcare Fraud Parallel Investigations: DEA diversion cases frequently overlap with federal healthcare fraud investigations. The same prescribing conduct that forms the basis of a diversion charge may also be charged as health care fraud or wire fraud under separate federal statutes. Coordinating defense strategy across both tracks is essential from the outset.
- DEA Surrenders and Voluntary Compliance Agreements: In some cases, surrendering a DEA registration or entering a compliance agreement with the agency may represent a better outcome than protracted litigation. Evaluating whether and how to negotiate these arrangements requires an attorney who has worked both sides of the federal enforcement table.
- Grand Jury Target and Subject Letters: Receiving a letter identifying you as a target or subject of a federal grand jury investigation is not the beginning of the end. It is the point at which representation becomes most urgent. How a target responds in the weeks following a grand jury letter can significantly affect the ultimate outcome.
What to Do If You Think You Are Under DEA Investigation
If a DEA diversion investigator has contacted your office, presented credentials, requested records, or asked to speak with you or your staff, treat that contact as the start of a legal proceeding, not an informal inquiry. Anything you say to a federal investigator can be used against you, including statements that seem helpful or innocuous. Many prosecutorial cases have been built substantially on a target’s own statements during what they believed to be a routine administrative visit.
Document everything you know about any contact with federal agents: the date, the agent’s name and badge number if provided, what was requested, and what if anything was said. Do not attempt to reconstruct, amend, or supplement records after government contact, even if you believe the existing records are incomplete. Alterations made after the government’s interest becomes known can give rise to obstruction charges that are distinct from and potentially more damaging than the underlying diversion allegations.
DEA administrative inspections of registered practitioners can occur without a warrant, but there are limits to that authority. An attorney can advise on what access must be granted, what records fall within the scope of an administrative inspection versus what requires a subpoena or warrant, and how to assert those limits without creating the appearance of obstruction. Federal criminal cases in the Southern District of New York are tried in the Thurgood Marshall United States Courthouse at 40 Foley Square. Eastern District of New York cases proceed at the federal courthouse in Brooklyn at 225 Cadman Plaza East. Both districts have active diversion enforcement dockets, and the United States Attorneys’ offices in both jurisdictions have designated healthcare fraud and drug diversion units.
State-level consequences run concurrently. New York’s Office of Professional Medical Conduct can initiate license proceedings based solely on a DEA administrative action, without waiting for a criminal conviction. The New York State Board of Pharmacy operates similarly. Coordinating the federal and state defense from a single strategic vantage point avoids the common mistake of treating each proceeding as separate and independent when the underlying facts are identical.
Why Jason Goldman for a New York DEA Diversion Case
Jason Goldman began his career as a Brooklyn prosecutor, rising through the ranks by handling serious felony matters before transitioning to criminal defense. That prosecutorial background matters in a diversion case because understanding how federal investigators build a case, what evidence they prioritize, and where they are likely to overreach gives defense counsel a genuine advantage in the pre-charge phase. He has handled pre-arrest investigations, taken cases through federal trial, and managed the sentencing and appellate phases of complex federal prosecutions.
The firm’s practice is deliberately selective and high-stakes. Goldman has represented corporate executives in finance, real estate, and hospitality, as well as doctors, lawyers, and professionals from industries where a federal investigation carries immediate reputational and professional consequences alongside the legal ones. DEA diversion matters fit precisely within that profile: the target is typically a licensed professional, the stakes include career and liberty, and the investigation is often underway before anyone outside the government is aware of it.
On matters that attract public attention, Goldman has a demonstrated capacity to manage the media dimension strategically, drawing on relationships with journalists, public relations professionals, and crisis management specialists when that serves the client. Equally, for clients who need the investigation handled with complete discretion, that same network operates in the other direction, helping to keep matters private during sensitive phases. The New York Post has called him “high-powered,” and Fox 5’s Rosanna Scotto has said simply: “Need a good lawyer, call him.” Goldman is a member of the National Association of Criminal Defense Lawyers, the New York State Association of Criminal Defense Lawyers, and serves on the Criminal Courts Committee of the New York City Bar Association. As a New York DEA diversion defense attorney, he brings the same preparation, judgment, and trial-tested instinct to every phase of representation.
Questions People Ask About DEA Diversion Cases in New York
What does DEA “diversion” actually mean in a federal investigation?
Diversion refers to the redirection of legally manufactured controlled substances away from their intended, lawful medical use and into illegal channels. Federal law imposes obligations on every participant in the distribution chain, from manufacturers to distributors to prescribers to pharmacies. When investigators believe any participant is failing those obligations, whether through negligence, recklessness, or intentional misconduct, a diversion investigation can be initiated. The term covers a wide range of conduct, from a physician writing prescriptions outside the bounds of legitimate medical practice to a pharmacy filling prescriptions it knows are fraudulent.
Can a DEA investigation result in both criminal charges and loss of my medical license?
Yes, and those consequences can occur on different timelines. Federal criminal prosecution requires proof beyond a reasonable doubt and proceeds through the U.S. District Courts. DEA registration revocation is an administrative proceeding with a lower burden of proof. New York State professional licensing proceedings operate under state administrative law. All three can proceed simultaneously or in sequence, and an adverse outcome in one can accelerate or complicate the others. Defense strategy must account for all three tracks from the outset.
Do I have to let a DEA diversion investigator into my office or practice?
DEA registrants, meaning holders of DEA registrations to handle controlled substances, are subject to administrative inspections without a warrant under the Controlled Substances Act. However, the scope of that authority is not unlimited. What records must be produced, what physical areas are subject to inspection, and what statements you are required to make are questions that depend on specific statutory authority and how it has been interpreted by federal courts. Retaining counsel before any inspection or voluntary interview with DEA agents is the most important step a registrant can take.
What is an “order to show cause” from the DEA?
An order to show cause is the DEA’s mechanism for initiating proceedings to revoke or suspend a practitioner’s DEA registration. It is not a criminal charge. It initiates an administrative proceeding before a DEA Administrative Law Judge, with the burden on the registrant to demonstrate that continued registration is consistent with the public interest. Responding to an order to show cause requires administrative law expertise that differs from courtroom criminal defense, though both may be needed simultaneously when criminal charges are pending alongside the administrative action.
How long does a DEA diversion investigation typically take before charges are filed?
There is no fixed timeline. Some investigations result in charges within months of the triggering event. Others unfold over several years, particularly when investigators are building a larger conspiracy case involving multiple targets across a prescription drug network. The extended timeline creates both risk and opportunity for someone under investigation. The longer the investigation runs without charges, the more time there is for counsel to gather facts, engage with prosecutors, and potentially resolve the matter short of indictment.
What is the difference between being a “target” and a “subject” of a federal grand jury investigation?
A target is someone the government believes has committed a crime and against whom the grand jury is actively considering an indictment. A subject is someone whose conduct falls within the scope of the investigation but who has not yet been identified as a target. Both designations warrant immediate legal representation. The distinction matters because it informs how aggressively prosecutors are likely to move and what strategic options counsel can realistically pursue, including cooperation discussions, tolling agreements, or pre-indictment resolution.
Can a New York prescriber lose their DEA registration without being convicted of a crime?
Yes. DEA registration proceedings are civil administrative matters, not criminal prosecutions. The DEA can revoke a registration based on a finding that continued registration would be inconsistent with the public interest, a determination that does not require a criminal conviction and applies a preponderance of the evidence standard rather than proof beyond a reasonable doubt. A prescriber can face registration revocation based solely on administrative findings about prescribing patterns, recordkeeping failures, or professional misconduct findings by a state licensing board.
If I cooperate with DEA investigators early, does that help me avoid charges?
Early cooperation without legal counsel is one of the most common and consequential mistakes made by professionals facing diversion investigations. Cooperation can be valuable, but only when structured strategically with the advice of a federal criminal defense attorney who has assessed the full scope of the government’s case. Unguided cooperation frequently produces admissions that strengthen the government’s case and foreclose defenses that would otherwise be available. Whether and how to engage with investigators is a decision that should never be made without counsel.
Are patients a source of evidence in DEA diversion cases against prescribers?
Frequently, yes. DEA investigators routinely interview patients whose names appear on flagged prescription records. They look for patients who will testify that prescriptions were issued without a meaningful examination, that they obtained prescriptions in exchange for cash, or that the prescriber was aware the medications were being sold. In undercover operations, agents have posed as patients to obtain what they characterize as prescriptions written without legitimate medical purpose. Patient interviews are often among the most damaging evidence gathered against a physician or advanced practice provider.
How does a prescription drug monitoring program database affect a diversion defense?
New York’s Prescription Monitoring Program Registry maintains records of every controlled substance prescription dispensed in the state. DEA investigators and federal prosecutors use this data to construct statistical analyses comparing a prescriber’s patterns against regional and specialty-specific benchmarks. High-volume outliers become investigation targets. Understanding how to contextualize and challenge that statistical evidence, by reference to patient population, specialty practice, or case mix, is a central element of diversion defense for prescribers.
DEA Diversion Defense Representation Across New York City and the Surrounding Region
The Law Offices of Jason Goldman represents clients throughout New York City and the broader metropolitan region. In Manhattan, the firm serves clients across Midtown, the Upper East Side, the Upper West Side, Tribeca, SoHo, the Financial District, and Washington Heights, where many of the city’s medical practices, pharmacies, and healthcare institutions are concentrated. In Brooklyn, the firm represents practitioners and registrants from Park Slope, Bay Ridge, Borough Park, Flatbush, Crown Heights, and Williamsburg. Queens-based clients in Flushing, Jamaica, Forest Hills, Astoria, and Long Island City, where dense medical communities serve some of the city’s most diverse patient populations, are also served. The firm represents clients in the Bronx, including Riverdale, Pelham Parkway, and the South Bronx, as well as Staten Island.
Beyond the five boroughs, the firm’s representation extends to clients in Westchester County, Nassau County, and Suffolk County on Long Island, where suburban healthcare practices and pharmacy networks face the same federal enforcement environment as their urban counterparts. Clients in New Jersey, particularly in Bergen and Hudson counties given their proximity to the Southern and Eastern Districts of New York, are also served. For practitioners facing federal investigations with New York nexus regardless of where they are physically located, Goldman is admitted to the Southern and Eastern Districts of New York and accepts pro hac vice admissions throughout the country for matters warranting his representation.
New York City DEA Diversion Defense Attorney: Reach Out Now
A federal diversion investigation does not pause while you decide what to do next. The investigation that has already been underway for months does not get smaller with time. For medical professionals, pharmacists, distributors, and others whose DEA registration and livelihood are at risk, the question is not whether to retain a New York City DEA diversion defense attorney, but when. For someone facing this situation, the answer is now, before the first subpoena is answered, before the first interview with a federal agent, and before the government’s early advantage becomes insurmountable.
Jason Goldman brings prosecutorial experience, trial-tested judgment, and a demonstrated record of high-stakes representation to clients whose careers and freedom depend on getting the defense right. Contact the Law Offices of Jason Goldman to discuss your situation directly.
